Wolfe Research downgraded Vera Therapeutics (VERA) to Peer Perform from Outperform without a price target The firm sees limited near-term upside in the shares given a lack of catalysts, increasing competitive pressure and “fading” takeover prospects. Vera’s lead in immunoglobulin A nephropathy is shrinking with the likely November approval of Otsuka’s sibeprenlimab, which could be a first-to-market therapy with more convenient dosing, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Millions in Insider Buying Point to These 2 Stocks — Here’s What It Could Signal
- Vera Therapeutics Inc put volume heavy and directionally bearish
- Vera Therapeutics Inc call volume above normal and directionally bullish
- 3 Best Stocks to Buy Now, 6/9/2025, According to Top Analysts
- U.S. payrolls rise 139,000, Broadcom reports Q2 beat: Morning Buzz